Links zur Industrie

Display #
#	Web Link	Hits
1	ZyStor Therapeutics, Inc. (en) ZyStor has developed a Glycosylation Independent Lysosomal Targeting (GILT) technology that aims to improve delivery of therapeutic enzymes to cells. Additionally, the half-life of these enzymes is increased. - 02OCT2009	267
2	Genzyme Corporation (en) Genzyme, a US biotech company, is a big player on the global market. Myozyme® is one of Genzyme's many products. Since 2006, it is approved for the use in enzyme replacement therapy for Pompe disease. - 02OCT2009	140
3	Genzyme GmbH (de) Genzyme Deutschland gehört zur weltweit agierenden Genzyme Corporation. Eines der vielen Produkte des Biotech-Unternehmens ist Myozyme®, das seit 2006 zur Enzymersatztherapie bei Morbus Pompe zugelassen ist. - 02OKT2009	187
4	Amicus Therapeutics, Inc. (en) Amicus Therapeutics develop pharmacological chaperones for oral therapies. One of the chaperones, AT2220, is a candidate for the therapy of Pompe disease. - 02OCT2009	237
5	Shire plc (en) Shire is a biopharmaceutical company with a wide range of products. For their Human Genetic Therapies (HGT) business, Shire acquired TKT in 2005 and started a joint-venture with Amicus Therapeutics in 2008 to develop a Pompe therapy using a pharmacological chaperone named HGT-3510 (Shire) or AT2220 (Amicus Therapeutics). - 07OCT2009 Update: collaboration with Amicus is terminated. - 29OCT2009	146
6	BioMarin Pharmaceutical Inc. (en) BioMarin is a biopharmaceutical company involved in enzyme replacement therapy and small molecule therapeuticals. BioMarin's BMN-103 (in preclinical testing) is a version of recombinant human acid alpha-glucosidase (rhGAA) that is hoped to be delivered to tissues better than Genzyme's Myozyme® (approved for enzyme replacement therapy). - 07OCT2009	182

European Pompe Portal

Links zur Industrie